PTC Therapeutics (PTCT) Announces Strategic Pipeline Prioritization
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
PTC Therapeutics Announces Strategic Pipeline Prioritization
May 23, 2023 4:05 PM EDT- Preclinical and early research gene therapy programs discontinued -
- Expected reductions of approximately 15% in residual 2023 OPEX -
SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/ --Â PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the discontinuation of preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. PTC will continue its development and global commercialization of Upstaza, the first-ever approved... More



